drugset / Trial / NCT00152256

A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids

NCT00152256

Phase 3 Completed 239 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to determine the safety and efficacy effects of two doses of asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to premenopausal subjects with symptomatic uterine leiomyomata.

Timeline

Start
2003-09
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 10 mg Oral
Subject Asoprisnil Other / unclassified 25 mg Oral